All In Biotech

Drug Trial Radar · NCT01109173

Confirmatory Study Nepafenac 0.3%

Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain After Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Nov 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,120

Actual

Start

Jun 2010

Primary completion

May 2011

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Apr 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.

Conditions

  • Cataract

Interventions

  • Nepafenac Ophthalmic Suspension, 0.3%Drug

    Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

  • Nepafenac Ophthalmic Suspension, 0.1%Drug

    Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days

  • Nepafenac Ophthalmic Suspension 0.3% VehicleOther

    Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.

  • NEVANAC VehicleOther

    Nepafenac vehicle, one drop in affected eye three times daily, for 16 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients Cured at Day 14Time frame: Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Call Center For Trial Locations

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.